Delix

Our Director of Medicinal Chemistry and Head of CMC Milan Chytil on joining Delix: “I was impressed by the founders’ vision to translate rapidly re-emerging basic psychedelics research into clinical success. I’m excited to be involved in discovering novel psychiatric treatments.”

It's #BrainAwarenessWeek, a time to share the wonders of the brain. At #Delix, we are driven to advance novel therapeutics that #healthemind. Register for the @sxsw panel on March 15th on psychedelics & brain health: fal.cn/3mUFa

A study published by academics at @HopkinsMedicine, including Roland Griffiths, a professor in the Departments of Psychiatry & Neurosciences, demonstrates the long-lasting antidepressant effects of psilocybin-assisted therapy. Full research findings here: bit.ly/3hcaNFi

Today is #InternationalWomensDay. Join us in celebrating the achievements of all women forging change, including the accomplished women of #Delix helping to rewire the brain to heal the mind.

#Delix’s @DEOlsonLab, @RetsinaMeyer, and Kurt Rasmussen will be discussing #psychedelic drug discovery, #psychoplastogens, and the importance of neural plasticity in @NatureCustom and @CRiverLabs' webcast on March 31st at 11 am ET. Register here: fal.cn/3mFKj

Building upon research showing psychedelics promote neuroplasticity in the cortex, @DEOlsonLab's lab at @ucdavis developed the first non-hallucinogenic #psychoplastogens capable of eliciting therapeutic effects. Explore our founding science: fal.cn/3mDz2

"I am thrilled to be a part of the rebirth of the psychedelic revolution in neuropsychiatry at Delix! We have an excellent team sharing the passion for Rewiring the Brain to deliver new therapies & potential cures to patients.” - Senior Director of Pharmacology, Sharon Engel.

Register for the @sxsw 2022 Psychedelics for Therapeutics & Well-being panel discussion on March 15th, ft. an array of speakers including #Delix SAB member & renowned expert in psychopharmacology, addiction, & mental health, Dr. John Krystal! Sign up: fal.cn/3mtaz

According to @PsychToday, up to 1/3 of patients do not find relief from the first, or even second, antidepressant they are prescribed. Click here for information on treatment-resistant depression, one of the many conditions #Delix is working to address: fal.cn/3mqYe

We're working with our team, advisors, and partner network to advance #Delix's library of 1,000+ novel compounds into scalable, orally-bioavailable, take-home therapies. Find out how we're promoting sustained healing through our neuroplasticity #research: bit.ly/3D2cU7B

Curious to learn more about our groundbreaking #technologies? Head to our Publications page to see our team's peer-reviewed published journal articles and other world-class #innovation: fal.cn/3mfd7

"At #Delix, we are working on an impactful, new class of medicines that has the potential to transform the neuro space and we get to do it with talented, curious people - it doesn't get much better than this!" - Head of Corporate Strategy, @RetsinaMeyer.

Today is @WomenScienceDay! We recognize and thank all past, present, and future female scientists for the critical role they play in pioneering science and technology. A special shoutout to the incredible #Delix women helping lead the way. Representation matters.

A study led by professors at @Stanford & @YaleMed suggests damage to brain cells & cognitive dysfunction can occur even w/ mild cases of COVID-19. Learn about COVID's potential neurological effects & the need for treatments for a range of brain disorders: fal.cn/3lYwb

Our team keeps growing! Welcome Lisa Wilson, Sam Newcomer, and Natalie Petrossian to the #Delix family! Thrilled to have you all join us in our mission to rewire the brain to #healthemind by prioritizing innovation and rigor.

#Delix harnesses the power of non-hallucinogenic #psychoplastogens to revolutionize treatments for #mentalhealth conditions. Learn how we're pioneering neuroplasticity research to achieve selective rewiring of pathological neural circuits to #healthemind: bit.ly/3GlNG68

Catch #Delix Co-Founder & Chief Innovation Officer @DEOlsonLab & SAB member Florence Wagner as they speak at @ucdavis’ 22nd annual @SymposiumMiller today, Feb. 3rd and tomorrow, Feb. 4th. Register here to learn about cutting-edge research in chemistry: bit.ly/3B06fuP

“Delix represents nothing less than a revolution in neuropsychiatric therapeutics. We're unraveling the brain’s secrets & applying that information into creating novel therapeutics to ease the suffering of billions. I am confident we will change the world." - CSO, Kurt Rasmussen.

Non-hallucinogenic #psychedelic analogs show therapeutic potential for treating mental health disorders. @ScienceMagazine explores research building upon the work of @DEOlsonLab & #Delix to relieve neuropsychiatric conditions w/o triggering hallucinations: bit.ly/3G6Ay3T

Older populations haven't been spared by the opioid epidemic. A @JAMANetwork study on overdose deaths shows a need for increased screening for substance use disorders (SUD) in older adults. #Delix aims to help those patients. Access the study for findings: fal.cn/3lFPT